Last week, the odd couple of carbon nanotubes got married: Carbon Nanotechnologies Inc. (CNI) and C Sixty. The first produces single-wall carbon nanotubes. The second works with fullerenes, the most common of which are called "buckyballs."

Basically, this Rule Breaking combination brings together two types of nanotubes: single-wall carbon nanotubes for materials and electronics applications, and spherical carbon nanotubes for medical applications. Only our imagination can forecast what will ensue. We're dealing with unknown territory here, and the future of carbon nanotubes just got a little more exciting.

Small C Sixty is joining a company that already has about 450 customers, including some giants such as DuPont (NYSE:DD); joint development agreements with companies such as Entegris (NASDAQ:ENTG); and a marketing partner, Sumitomo (Pink Sheets: SSUMF), offering access to the market in Japan. CNI will prove a strong partner for C Sixty, with more than 100 patents, cash in the bank, a growing customer base, and access to domestic and foreign markets.

This is an opportunity for CNI to expand its market into medical applications using C Sixty's spherical buckyballs. These companies are still private, and they're laying the groundwork for what could be a very successful commercial venture.

C Sixty will have the benefit of concentrating on its medical applications without constantly worrying about the funding it will need in the future.

CNI will be able to combine spherical fullerenes with its single-wall carbon nanotubes, creating products and revenue streams. The combination of the two nanotubes may lead to new and never-imagined applications, new markets, new customers, increased revenue, and (hopefully) expanded earnings potential.

This merger, along with an expanding customer base, makes CNI an even more attractive initial public offering. Will 2005 be the year carbon nanotubes are introduced to the public?

If you're looking for the next growth company in groundbreaking fields such as nanotechnology, try our ultimate growth service, Motley Fool Rule Breakers.

Share your views with Carl (TMFBreakerCarl) and John (TMFBreakerJohn) on the Nanotechnology discussion board.

Carl Wherrett doesn't own shares of any company mentioned in this article. Neither does John Yelovich. You can reach them both by email. The Fool has a disclosure policy.